pharmaphorum December 22, 2025
2025 has been a reset year for BioMarin Pharmaceutical, and as 2026 approaches, it has reached a $4.8 billion deal to buy Amicus Therapeutics, further extending a renewed push into rare diseases.
The $14.50 per share agreement, if completed, will add two fast-growing treatments for two lysosomal storage disorders, Fabry and Pompe disease, plus a third drug in phase 3 testing for the rare kidney disease focal segmental glomerulosclerosis (FSGS).
It’s the second acquisition made by BioMarin since the company enticed former Roche dealmaker James Sabry to join the company, coming after it bought Inozyme for $270 million earlier this year, and the largest in its history.
By adding two products that are already on the market – oral Fabry...
Today's Sponsors
Today's Sponsor